These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 22683823

  • 1. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
    Nashan B, Gaston R, Emery V, Säemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC.
    Transplantation; 2012 Jun 15; 93(11):1075-85. PubMed ID: 22683823
    [Abstract] [Full Text] [Related]

  • 2. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L.
    Transpl Infect Dis; 2013 Apr 15; 15(2):150-62. PubMed ID: 23013440
    [Abstract] [Full Text] [Related]

  • 3. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.
    Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C.
    Transplantation; 2007 Dec 15; 84(11):1436-42. PubMed ID: 18091519
    [Abstract] [Full Text] [Related]

  • 4. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials.
    Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, Adamkovic A, Liu Q, Harler MB, Hahn C, Singh A.
    Transplant Proc; 2008 Jun 15; 40(5):1407-10. PubMed ID: 18589118
    [Abstract] [Full Text] [Related]

  • 5. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.
    Nashan B, Citterio F.
    Transplantation; 2012 Sep 27; 94(6):547-61. PubMed ID: 22941182
    [Abstract] [Full Text] [Related]

  • 6. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D, Martínez D, Gutiérrez E, López V, Gutiérrez C, García P, Cobelo C, Cabello M, Burgos D, Sola E, González-Molina M.
    Nefrologia; 2011 Sep 27; 31(1):27-34. PubMed ID: 21270910
    [Abstract] [Full Text] [Related]

  • 7. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H, Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 27; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [Abstract] [Full Text] [Related]

  • 8. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 9. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
    Rittà M, Costa C, Solidoro P, Sidoti F, Libertucci D, Boffini M, Rinaldi M, Baldi S, Cavallo R.
    Antiviral Res; 2015 Jan 27; 113():19-26. PubMed ID: 25446337
    [Abstract] [Full Text] [Related]

  • 10. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation.
    Ghassemieh B, Ahya VN, Baz MA, Valentine VG, Arcasoy SM, Love RB, Seethamraju H, Alex CG, Bag R, DeOliveira NC, Vigneswaran WT, Charbeneau J, Garrity ER, Bhorade SM.
    J Heart Lung Transplant; 2013 Jul 27; 32(7):701-6. PubMed ID: 23664526
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
    Haririan A, Morawski K, West MS, El-Amm JM, Doshi MD, Cincotta E, Alangaden GJ, Chandrasekar P, Gruber SA.
    Clin Transplant; 2007 Jul 27; 21(4):466-71. PubMed ID: 17645705
    [Abstract] [Full Text] [Related]

  • 12. The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation.
    Sheng L, Jun S, Jianfeng L, Lianghui G.
    Clin Transplant; 2015 Jun 27; 29(6):555-9. PubMed ID: 25851741
    [Abstract] [Full Text] [Related]

  • 13. Everolimus: preventing organ rejection in adult kidney transplant recipients.
    Dantal J.
    Expert Opin Pharmacother; 2012 Apr 27; 13(5):767-78. PubMed ID: 22404500
    [Abstract] [Full Text] [Related]

  • 14. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
    Havenith SH, Yong SL, van Donselaar-van der Pant KA, van Lier RA, ten Berge IJ, Bemelman FJ.
    Transplantation; 2013 Jan 15; 95(1):184-91. PubMed ID: 23222818
    [Abstract] [Full Text] [Related]

  • 15. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
    Andrés V, Castro C, Campistol JM.
    Nephrol Dial Transplant; 2006 Jul 15; 21 Suppl 3():iii14-7. PubMed ID: 16815851
    [Abstract] [Full Text] [Related]

  • 16. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting.
    Bocchi EA, Ahualli L, Amuchastegui M, Boullon F, Cerutti B, Colque R, Fernandez D, Fiorelli A, Olaya P, Vulcado N, Perrone SV.
    Transplant Proc; 2006 Apr 15; 38(3):937-42. PubMed ID: 16647515
    [Abstract] [Full Text] [Related]

  • 17. Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?
    Zuckermann A, Wang SS, Epailly E, Barten MJ, Sigurdardottir V, Segovia J, Varnous S, Turazza FM, Potena L, Lehmkuhl HB.
    Transplant Rev (Orlando); 2013 Jul 15; 27(3):76-84. PubMed ID: 23643624
    [Abstract] [Full Text] [Related]

  • 18. Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients.
    Ozaki KS, Câmara NO, Galante NZ, Camargo LF, Pacheco-Silva A.
    Int Immunopharmacol; 2005 Jan 15; 5(1):103-6. PubMed ID: 15589467
    [Abstract] [Full Text] [Related]

  • 19. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
    Lovric S, Kielstein JT, Kayser D, Bröcker V, Becker JU, Hiss M, Schiffer M, Sommerwerck U, Haller H, Strüber M, Welte T, Gottlieb J.
    Nephrol Dial Transplant; 2011 Sep 15; 26(9):3032-8. PubMed ID: 21310739
    [Abstract] [Full Text] [Related]

  • 20. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S, Baroletti SA.
    Pharmacotherapy; 2010 Oct 15; 30(10):1044-56. PubMed ID: 20874042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.